6 Ways to Spot a Predatory Journal

Predatory journals are scam publishers that charge authors fees upfront, but do not provide the service they promise. The majority of these predatory journals will take payments without ever publishing the work, while others publish articles without any form of an editorial or peer review process.

Understanding the Literature Search Process

Recently, our company Rx communications Ltd has been involved in proposals for a number of literature review projects – one where an original review and analysis required updating before publication, and others that were designed to find answers to fairly obscure or unusual questions. We find, with the start of the year, many of our clients looking for vendors for these types of projects, and so we thought it might be useful to share our experiences.

Competitive Intelligence and Competitor Strategy

Interesting article in PharmaVoice in April 2012 – regarding Competitive Intelligence and Competitor Strategy.  The article rightly points out that Pharma is leaving good intel on the table –by not developing relationships and using them effectively; or by taking a very high-minded attitude to informal sources of intel (e.g. conversations overheard at airports); or with…

Evidence matters… of course it does!

Ruairi O’Donnell writes in the March 2012 issue of Pharmaceutical Market Europe that evidence matters.  Of course it does. And particularly in market access activities, which is the context he addresses in his article. Some of the points he makes are very good: about payers as a group being a variety of different types of people…

The Absence of Clinical Trial Data: Attack on Pharma

One of our Twitter followers @HealthEcoDigest recently blogged a podcast with the BMJ editor-in-chief Fiona Godlee and neuroscientist Professor Colin Blakemore. In the podcast, they are discussing whether a false picture is being put forward by medical science. Although not a new issue, Fiona Godlee uses specific examples from the pharmaceutical industry. Additionally Colin Blakemore…